GGiantBullStocks

Capricor Therapeutics, Inc. (CAPR)

NASDAQ · Healthcare

$19.50+0.31%

As of Jul 20, 2026

Price history

Key statistics

Market cap
$983.37M
P/E ratio
EPS
Volume
1,649,759
52-week high
52-week low
Open
$19.68
Day high
$20.17
Day low
$18.93

Financial highlights

Fiscal yearRevenueNet incomeEPS
2025$0-$105.04M-$2.26
2024$22.27M-$40.47M-$1.15
2023$25.18M-$22.29M-$0.83
2022$2.55M-$29.02M-$1.18
2021$244.9K-$20.02M-$0.87

About Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

CEO
Linda Marbán
Employees
231
Country
US
IPO date
Feb 13, 2007

Similar stocks

Other Healthcare companies

Frequently asked questions

What is Capricor Therapeutics, Inc.'s stock price today?
CAPR is trading at $19.50 as of Jul 20, 2026.
What is Capricor Therapeutics, Inc.'s market cap?
Capricor Therapeutics, Inc. (CAPR) has a market capitalization of $983.37M.
Does Capricor Therapeutics, Inc. pay a dividend?
Capricor Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
What sector is Capricor Therapeutics, Inc. in?
Capricor Therapeutics, Inc. operates in the Healthcare sector.